Type 2 diabetes is characterised by progressive insulin secretory dysfunction and insulin resistance, which together drive chronic hyperglycaemia and associated microvascular and macrovascular ...
With the two active components, sitagliptin and metformin, Janumet has a comprehensive mechanism of action that targets all three key defects of T2DM for improved glycemic control: diminished insulin ...
Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...
CSPC Pharmaceutical Group Ltd. on Jan. 13 gained the National Medical Products Administration’s approval of Shanzeping (prusogliptin tablets; DBPR-108) as a novel oral dipeptidyl peptidase-IV (DPP-4) ...
A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor. Results: Initially, more than 50% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results